AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer | Anticancer Research
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA: #ASCO 2017 Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
Secondary cytoreductive surgery for recurrent ovarian cancer improves overall survival - BJMO
Targeted Therapy in Ovarian Cancer | Published in healthbook TIMES Oncology Hematology
Shannon Westin, MD, MPH, FASCO on X: "This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent # ovariancancer - DESKTOP III and SOC -1 #ASCO20 #SGOatASCO #gyncsm https://t.co/pHGWklYWKs" /
A trial looking at surgery for ovarian cancer that has come back (DESKTOP 3, ENGOT ov20) | Cancer Research UK
PPT - AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4) PowerPoint Presentation - ID:1402011
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer | NEJM
Cancers | Free Full-Text | Investigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study
ASCO 2020: AGO DESKTOP III Highlights Importance of Complete Resection in Recurrent Ovarian Cancer | PracticeUpdate
Study schema. CR, complete response; OS, overall survival; PD,... | Download Scientific Diagram
Cancers | Free Full-Text | Surgery in Recurrent Ovarian Cancer: A Meta-Analysis
Design of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian... | Download Scientific Diagram
Frontiers | Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
Design of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian... | Download Scientific Diagram
Epithelial ovarian cancer - The Lancet
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
PPT - An Oncology Exchange Activity PowerPoint Presentation, free download - ID:5600388
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
Journal of Gynecologic Oncology
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial - The Lancet Oncology
ESGO on X: "👋 Ready for the next #ENYGO webinar? Register now for our webinar with Andreas du Bois. He'll talk about DESKTOP III Trial Results: Do patients in recurrent ovarian cancer
